184 related articles for article (PubMed ID: 12171262)
1. Management of bronchiolitis: current practices in Ireland.
Cahill P; Finan E; Loftus BG
Ir Med J; 2002 Jun; 95(6):167-9. PubMed ID: 12171262
[TBL] [Abstract][Full Text] [Related]
2. Management of acute bronchiolitis: can evidence based guidelines alter clinical practice?
Barben J; Kuehni CE; Trachsel D; Hammer J;
Thorax; 2008 Dec; 63(12):1103-9. PubMed ID: 18723582
[TBL] [Abstract][Full Text] [Related]
3. Palivizumab use in preterm neonates.
Kingston S; Murphy BP
Ir Med J; 2010 May; 103(5):141-4. PubMed ID: 20666085
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and management of bronchiolitis.
American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis
Pediatrics; 2006 Oct; 118(4):1774-93. PubMed ID: 17015575
[TBL] [Abstract][Full Text] [Related]
5. [Management of bronchiolitis in infants].
Soins Pediatr Pueric; 2001 Oct; (202):16-21. PubMed ID: 11949584
[No Abstract] [Full Text] [Related]
6. Bronchiolitis: from empiricism to scientific evidence.
Carraro S; Zanconato S; Baraldi E
Minerva Pediatr; 2009 Apr; 61(2):217-25. PubMed ID: 19322125
[TBL] [Abstract][Full Text] [Related]
7. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
8. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.
Bradley JP; Bacharier LB; Bonfiglio J; Schechtman KB; Strunk R; Storch G; Castro M
Pediatrics; 2005 Jan; 115(1):e7-14. PubMed ID: 15629968
[TBL] [Abstract][Full Text] [Related]
9. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
[TBL] [Abstract][Full Text] [Related]
10. Preventing RSV bronchiolitis in vulnerable infants: the role of palivizumab.
Fitzgerald DA
Paediatr Respir Rev; 2009 Sep; 10(3):143-7. PubMed ID: 19651385
[TBL] [Abstract][Full Text] [Related]
11. Respiratory syncytial virus infections: characteristics and treatment.
Chidgey SM; Broadley KJ
J Pharm Pharmacol; 2005 Nov; 57(11):1371-81. PubMed ID: 16259768
[TBL] [Abstract][Full Text] [Related]
12. Racemic epinephrine compared to salbutamol in hospitalized young children with bronchiolitis; a randomized controlled clinical trial [ISRCTN46561076].
Langley JM; Smith MB; LeBlanc JC; Joudrey H; Ojah CR; Pianosi P
BMC Pediatr; 2005 May; 5(1):7. PubMed ID: 15876347
[TBL] [Abstract][Full Text] [Related]
13. RSV: Management of the acute episode.
Hodge D; Chetcuti PA
Paediatr Respir Rev; 2000 Sep; 1(3):215-20. PubMed ID: 12531082
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic and therapeutic approach to acute bronchiolitis in hospitalized children in Israel: a nationwide survey.
Offer I; Ashkenazi S; Livni G; Shalit I
Isr Med Assoc J; 2000 Feb; 2(2):108-10. PubMed ID: 10804929
[TBL] [Abstract][Full Text] [Related]
15. [Current management of acute bronchiolitis in Tunisia].
Menif K; Kechaou W; Bouziri A; Khaldi A; Belhaj S; Hamdi A; Ben Jaballah N
Tunis Med; 2007 Aug; 85(8):665-8. PubMed ID: 18254288
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis--a clinical trial.
Karadag B; Ceran O; Guven G; Dursun E; Ipek IO; Karakoc F; Ersu RH; Bozaykut A; Inan S; Dagli E
Respiration; 2008; 76(3):283-7. PubMed ID: 18042975
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab efficacy in preterm infants with gestational age < or = 30 weeks without bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Sagot P; Quantin C; Huet F; Gouyon JB;
Pediatr Pulmonol; 2007 Mar; 42(3):189-92. PubMed ID: 17243184
[TBL] [Abstract][Full Text] [Related]
18. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of palivizumab in infants with congenital heart disease.
Yount LE; Mahle WT
Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
